Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Regeneron has invested heavily in manufacturing capabilities to meet these demands. Beyond clinical development, Regeneron actively engages with the hearing loss community, including advocacy groups, ...

We have more than 30 that can help level up your clinical skills. "Hi. This is Shalin from CDOCS. Today's tip of the day is about periodontal attachment loss. "Not all periodontal attachment loss is ...

Shelby Knowles/Bloomberg via Getty Images Zepbound led to more long-term weight loss than Wegovy in a new clinical trial from drugmaker Eli Lilly. Lilly officials said 31% of people taking ...

The language used by healthcare professionals to describe pregnancy loss exacerbates the grief and trauma experienced by some individuals, a report has concluded. A team from University College London ...

LOS ANGELES, Aug. 13, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today announced that the ...

Clinical Research Associates is conducting a drug study on glucagon-like peptide 1 (GLP-1) agonists, a class of medications used to treat Type 2 diabetes and weight loss. “Everybody wants to ...

A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo.

The next frontier for pharma in the obesity space is improving the quality of weight loss. The approved GLP ... the FDA be looking for in terms of a clinical endpoint? Regeneron Chief Scientific ...

Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its experimental drug asundexian for prevention of stroke and systemic embolism for patients with the heart-rhythm ...

Steph explained further, saying, “My hunch is that [the] wall that I’m coming up against is coming from that Gen-X parent’s own attachment ... Steph capped off her clinical observations ...